Page 170 of 1,034: studies 1,691 to 1,700 of 10,336, newest first. Back to the depression overview
Current Molecular Pharmacology August 9, 2023 MIng Tatt Lee, Yu-Cheng Ho 2 citations
Keywords: Ketamine, depression, antidepressant, 2R6R-hydroxynorketamine, major depressive disorder, Spravato
Journal of Education, Health and Sport August 8, 2023 Anna Jaremek, Joanna Kępa, Norbert Kandefer et al.
In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment. Depression, a widespread psychological malady affecting countless individuals across the globe, often proves stubborn against existing treatment modalities, necessitating exploration...
Research Square August 7, 2023 Rong Xu, Yiheng Pan, Maria P Gorenflo et al. preprint
Abstract Ketamine, including esketamine, is an effective treatment for patients with treatment-resistant depression (TRD); however, its long-term efficacy in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs) data from 93 million patients from 56 health care...
European Neuropsychopharmacology August 7, 2023 Natacha Perez, Florent Langlest, Luc Mallet et al. 85 citations
Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...
International Journal of Molecular Sciences August 7, 2023 Alexander Pilozzi, Simmie Foster, David Mischoulon et al. 16 citations
Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...
Current Medical Research and Opinion August 3, 2023
OBJECTIVE: To describe access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD) with private or public insurance. METHODS: Adults with ≥1 claim for esketamine nasal spray were selected from Clarivate's Real World Data product (January 2016-March 2021). Patients with evidence of TRD initiating esketamine (index date) after 05 March 2019...
JAMA Network Open August 1, 2023 Chunfeng Xiao, Jia Zhou, Anning Li et al.
Importance: Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies. Objective: To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral...
Journal of Psychopharmacology August 2023 Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li et al.
Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear. We enrolled 65 patients with TRD, comprising 33 who received a single infusion of 0.5 mg/kg ketamine and 32 who received a placebo infusion. The...
Journal of Psychopharmacology August 2023 Matthew Burrows, Vasileia Kotoula, Ottavia Dipasquale et al.
Resting state connectivity studies link ketamine's antidepressant effects with normalisation of the brain connectivity changes that are observed in depression. These changes, however, usually co-occur with improvement in depressive symptoms, making it difficult to attribute these changes to ketamine's effects per se. Our aim is to examine the effects of ketamine in brain connectivity, 2 h after...
Journal of Psychiatric Research August 1, 2023 Igor D. Bandeira, Gustavo C. Leal, Fernanda S. Correia-Melo et al.
There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at...